Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 13, 2008 - Issue 3
Submit an article Journal homepage
195
Views
23
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for adrenocortical carcinoma

Alfredo Berruti University of Turin, Department of Clinical and Biological Science, Oncologia Medica, Azienda Ospedaliera San Luigi, Regione Gonzole 10, 10043 Orbassano, Italy +39 0119026512; +39 0119026992; [email protected]
,
Anna Ferrero University of Turin, Department of Clinical and Biological Science, Oncologia Medica, Azienda Ospedaliera San Luigi, Regione Gonzole 10, 10043 Orbassano, Italy +39 0119026512; +39 0119026992; [email protected]
,
Paola Sperone University of Turin, Department of Clinical and Biological Science, Oncologia Medica, Azienda Ospedaliera San Luigi, Regione Gonzole 10, 10043 Orbassano, Italy +39 0119026512; +39 0119026992; [email protected]
,
Fulvia Daffara Medicina Interna, Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy +39 0119026427; +39 0119026992; [email protected]
,
Giuseppe Reimondo Medicina Interna, Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy +39 0119026427; +39 0119026992; [email protected]
,
Mauro Papotti Anatomia Patologica, Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy +39 0119026486; +39 0119026992; [email protected]
,
Luigi Dogliotti University of Turin, Department of Clinical and Biological Science, Oncologia Medica, Azienda Ospedaliera San Luigi, Regione Gonzole 10, 10043 Orbassano, Italy +39 0119026512; +39 0119026992; [email protected]
,
Alberto Angeli Medicina Interna, Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy +39 0119026427; +39 0119026992; [email protected]
&
Massimo Terzolo Medicina Interna, Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy +39 0119026427; +39 0119026992; [email protected]
 show all
Pages 497-509 | Published online: 02 Sep 2008

Bibliography

  • Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000;88:711-36
  • Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001;25:914-26
  • Allolio B, Fassnacht M. Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;60:273-87
  • Libè R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007;14:13-28
  • Schteingart DE. Current perspective in the diagnosis and treatment of adrenocortical carcinoma. Rev Endocr Metab Disord 2001;2:323-33
  • Phan AT. Adrenal cortical carcinoma: review of current knowledge and treatment practices. Hematol Oncol Clin North Am 2007;21:489-507
  • Soon PS, Libe R, Benn DE, et al. Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Ann Surg 2008;247:157-64
  • Almeida MQ, Latronico AC. The molecular pathogenesis of childhood adrenocortical tumors. Horm Metab Res 2007;39:461-6
  • Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 2001;98:9330-1
  • Macfarlane DA. Cancer of the adrenal cortex: the natural history, prognosis, and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958;23:155-86
  • Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol 1978;120:660-5
  • Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253 patients series from the French Association of Endocrine Surgeons Study Group. World J Surg 2001;25(7):891-7
  • Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996;119(2):161-70
  • Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 1997;122(6):1212-8
  • Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007;356:2372-80
  • Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6:719-26
  • Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992;112:963-70
  • Schteingart DE, Motazedi A, Noonan RA, et al. Treatment of adrenal carcinomas. Arch Surg 1982;117:1142-6
  • Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002;20:941-50
  • Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006;91:2650-5
  • Fassnacht M, Hahner S, Koscher AC, et al. The German Adrenocortical Cancer Registry. Analysis of the first 333 patients. Abstracts of the 88th annual meeting of the Endocrine Society; 2006; P2 781
  • Schteingart DE, Doherty GM, Gauger TJ, et al. Management of patients with adrenal cancer: recommendation of an international consensus conference. Endocr Relat Cancer 2005;12(3):667-80
  • Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001;92(5):1113-21
  • Hahner S. Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 2005;6(4):386-94
  • Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72(11):3145-55
  • Venkatesh S, Hickey RC, Sellin RV, et al. Adrenal cortical carcinoma. Cancer 1989;64(3):765-9
  • Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322(17):1195-201
  • Decker RA, Elson P, Hogan TF, et al. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 1991;1106:1006-13
  • Haak HR, Hermans J, Van De Velde CJ. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994;947-51
  • Barzon L, Fallo F, Sonino N, et al. Adrenocortical carcinoma: Experience in 45 patients. Oncology 1997;54:490-6
  • Williamson SK, Lew D, Miller GJ, et al. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 2000;88(5):1159-65
  • Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenilchloroetane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001;1385-92
  • Terzolo M, Pia A, Berruti A, Osella G, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000;2234-8
  • Van Slooten H, Moolenaar AJ, Van Seters AP, et al. The treatment of adrenocortical carcinoma with o,p'DDD: prognostic simplifications of serum level monitoring. Eur J Cancer Clin Oncol 1984;20:47-53
  • Ahlman H, Khorram-Manesh A, Jansson S, et al. Cytotoxic treatment of adrenocortical carcinoma. World J Surg 2001;25(7):927-33
  • Allolio B, Hahner S, Weismann D, et al. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004;60:273-87
  • Bates SE, Shieh CY, Mickley LA, et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 1991;73(1):18-29
  • Villa R, Orlandi L, Berruti A, et al. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int J Oncol 1999;14(1):133-8
  • Abraham JS, Bakke A, Rutt B, et al. A Phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002;94(9):2333-43
  • Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000;11(10):1281-7
  • Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998;83(10):2194-200
  • Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective Phase II trial. Endocr Relat Cancer 2005;12(3):657-66
  • Bonacci R, Gigliotti A, Baudin E, et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer 1998;78(4):546-9
  • Bukowski RM, Wolfe M, Levine HS, et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 1993;11(1):161-5
  • Schlumberger M, Brugieres L, Gicquel C, et al. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991;67(12):2997-3000
  • Van Slooten H, Van Oosterom AT. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983;67(4):377-9
  • Burgess MA, Legha SS, Sellin RV. Chemotherapy with cisplatinum and etoposide (UP16) for patients with advanced adrenal cortical carcinoma (ACC) [abstract no 188]. Proc Ann Soc Clin Oncol 1993;12
  • Menefee M, Edgerly M, Velarde M, et al. The efficacy of combination chemotherapy with cisplatin and gemcitabine in patients with advanced adrenal cortical carcinoma (ACC) [abstract no 12033]. Proc Ann Soc Clin Oncol 2006;24
  • Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res 2001;1191-6
  • Bertherat J, Coste J, Bertagna X. Adjuvant mitotane in adrenocortical carcinoma. New Engl J Med 2007;357(12):1256-7
  • Rodger SE, Evans DB, Lee JE, et al. Adrenalcortical carcinoma. Surg Oncol Clin N Am 2006;15(3):535-53
  • This information is available as a free service in Europe, provided by the company distributing mitotane: Available from: [email protected]
  • Martin LP, Hamilton TC, Schilder RJ. Platinum resistence. The role of DNA repair pathways. Clin Cancer Res 2008;14(5):1291-5
  • Barlaskar FM, Hammer GD. The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab Disord 2007;8(4):343-8
  • Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr-Relat Cancer 2006;13(Suppl 1):S33-43
  • Samani AA, Yakar S, Leroith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28(1):20-47
  • Hotta M, Baird A. Differential effects of transforming growth factor type beta on the growth and function of adrenocortical cells in vitro. Proc Natl Acad Sci USA 1986;83:7795-9
  • Feige JJ, Cochet C, Savona C, et al. Transforming growth factor beta 1: an autocrine regulator of adrenocortical steroidogenesis. Endocr Res 1991;17:267-79
  • De Fraipont F, El Atifi M, Gicquel C, et al. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J Clin Endocrinol Metab 2000;85:4734-41
  • Ilvesmaki S, Kahri AI, Miettinen PJ, et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 1993;77:852-8
  • Vittet D, Ciais D, Keramidis N, et al. Paracrine control of the adult adrenal cortex vasculature by vascular endothelial growth factor. Endocr Res 2000;26(4):843-52
  • Weber MM, Auerhammer CJ, Kiess W, et al. Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. Eur J Endocrinol 1997;136(3):296-303
  • Turner HE, Harris AL, Melmed S, et al. Angiogenesis in endocrine tumors. Endocr Rev 2003;24(5):600-32
  • Bernini A, Moretti AG, Bonadio M, et al. Angiogenesis in Human Normal and Pathologic Adrenal Cortex. J Clin Endocrinol Metabol 2002;87(11):4961-5
  • Allolio B. Tissue Arrays as Tools to Identify New Treatment Targets. International Adrenal Cancer Symposium, Ann Arbor; 14-25 March, 2008; personal presentation
  • First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT). Available from: www.firm-act.org
  • Bates S, Kang M, Meadows B, et al. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer 2001;92:1577-90
  • Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001;61:749-58
  • Walker J, Martin C, Callaghan R. Inhibition of P-glycoprotein function by XR9576 in a solid tumor model can restore anticancer drug efficacy. Eur J Cancer 2001;40:594-605
  • Martin C, Berridge G, Mistry P, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 1999;128:403-11
  • Samnotra V, Vassilopoulou-Sellin R, Fojo AT, et al. A Phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC) [abstract no 15527]. Proc Ann Soc Clin Oncol 2007;25
  • Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008; in press
  • Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4(6):423-36
  • Hammer G. Wnt Signaling in Adrenocortical Stem Cells and ACC. International Adrenal Cancer Symposium Ann Arbor; 2008; personal presentation
  • Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 2008;15:1-6
  • Lee JE, Berger DH, El-Naggar AK, et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995;118:1090-8
  • Henley DJ, Van Heerden JA, Grant CS, et al. Adrenal cortical carcinoma: a continuing challenge. Surgery 1983;94:926-31
  • Bodie J, Novick AC, Pontes JA, et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 1989;141(2):257-60
  • Weiss LM, Medeiros LJ, Vickery AL JR. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989;13:202-6
  • Volante M, Buttigliero C, Greco E, et al. Pathological and molecular features of adrenocortical carcinoma. J Clin Pathol 2008;61:787-93
  • Fassnacht M. German Adrenal Cancer Registry: Can Registries Help to Identify Prognostic Factors. International Adrenal Cancer Symposium Ann Arbor; 2008; personal presentation
  • Terzolo M, Boccuzzi A, Bovio S, et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology 2001;57:176-82
  • Goldblum JR, Shannon R, Kaldjian EP, et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol 1993;6:663-8
  • Advani A, Vaikkakara S, GILL MS, et al. Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review. J Clin Pathol 2008; in press
  • Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999;134:181-5
  • Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 2008;55:49-55
  • Sredni ST, Alves VA, Latorre MDO R, Zerbini MC. Adrenocortical tumours in children and adults: a study of pathological and proliferation features. Pathology 2003;35:130-5
  • Kirschner LS. Emerging Treatment Strategies for Adrenocortical Carcinoma: a new hope. J Clin Endocrinol Metab 2006;91:14-21
  • Available from: www.clinicaltrials.gov for more details
  • Vassilopoulu-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1994;73(5):1533-5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.